TriSalus Life Sciences Announces Late Breaker And Additional Data Presentations On Liver Metastases And Pancreatic Cancer At The Society For Immunotherapy Of Cancer 2023 Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
TriSalus Life Sciences (NASDAQ:TLSI) will present new data from its clinical development pipeline at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. The presentations will include data on liver metastases and pancreatic cancer, and will feature the company's novel delivery technology integrated with immunotherapy.
October 25, 2023 | 1:09 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
TriSalus Life Sciences will present new data at the SITC 2023, which could potentially impact the company's reputation and stock price depending on the results.
The presentation of new data at a major conference like SITC can have a significant impact on a company's reputation in the scientific community. Positive results could boost the company's stock price, while negative results could have the opposite effect. However, without knowing the specifics of the data, it's difficult to predict the exact impact on the stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100